<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bupivacaine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bupivacaine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bupivacaine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11931" href="/d/html/11931.html" rel="external">see "Bupivacaine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13100" href="/d/html/13100.html" rel="external">see "Bupivacaine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708636"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Obstetrical anesthesia (injection only):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There have been reports of cardiac arrest with difficult resuscitation or death during use of bupivacaine for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of bupivacaine is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risk of potential adverse embolic effects resulting from inadvertent intravascular injection (subacromial injection only):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Inadvertent intravascular injection could cause bupivacaine droplets to be deposited in the pulmonary and other capillary beds. Administer bupivacaine into the subacromial space at the end of arthroscopic shoulder surgery. Direct arthroscopic visualization must be used to confirm proper placement of the needle tip before injecting bupivacaine.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F142923"><span class="drugH1">Brand Names: US</span>
<ul>
<li>BUPivacaine Fisiopharma;</li>
<li>BUPivacaine Spinal;</li>
<li>Marcaine;</li>
<li>Marcaine Preservative Free;</li>
<li>Marcaine Spinal;</li>
<li>P-Care M [DSC];</li>
<li>Posimir;</li>
<li>Sensorcaine;</li>
<li>Sensorcaine-MPF;</li>
<li>Xaracoll</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866127"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Marcaine;</li>
<li>Marcaine Spinal;</li>
<li>Sensorcaine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F142962"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Local Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F142927"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3c1e27cf-683e-49d4-954f-07a7d930dae9">Analgesia/Anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Analgesia/Anesthesia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Implant: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Analgesia, postsurgical:</b> 300 mg (3 × 100 mg implants) as a single dose placed into the inguinal hernia repair surgical site.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Injection: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Do not use solutions containing preservatives for caudal or epidural block.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Local anesthesia: Infiltration:</b> 0.25% infiltrated locally; maximum: 175 mg. <b>Note:</b> Aspiration should be performed prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20216035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20216035'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Caudal block</b> (preservative free): 15 to 30 <b>mL</b> of 0.25% or 0.5%</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Epidural block</b> (other than caudal block; preservative free): Administer in 3 to 5<b> mL</b> increments, allowing sufficient time to detect toxic manifestations of inadvertent IV or intrathecal administration: 10 to 20 <b>mL</b> of 0.25% or 0.5%</p>
<p style="text-indent:-2em;margin-left:8em;">Surgical procedures requiring a high degree of muscle relaxation and prolonged effects <b>only</b>: <b>Note:</b> Not to be used in obstetrical cases: 10 to 20 <b>mL</b> of 0.75%</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Peripheral nerve block:</b> 5 <b>mL</b> of 0.25% or 0.5%; maximum: 400 mg/day</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Sympathetic nerve block:</b> 20 to 50 <b>mL</b> of 0.25%</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Retrobulbar anesthesia:</b> 2 to 4 <b>mL</b> of 0.75%</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Spinal anesthesia:</b> Preservative free solution of 0.75% bupivacaine in 8.25% dextrose:</p>
<p style="text-indent:-2em;margin-left:8em;">Lower extremity and perineal procedures: 1 <b>mL</b></p>
<p style="text-indent:-2em;margin-left:8em;">Lower abdominal procedures: 1.6 <b>mL</b></p>
<p style="text-indent:-2em;margin-left:8em;">Labor and normal vaginal delivery: 0.8 <b>mL</b> (higher doses may be required in some patients)</p>
<p style="text-indent:-2em;margin-left:8em;">Cesarean delivery: 1 to 1.4 <b>mL</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Combined spinal-epidural (CSE) technique for labor analgesia (off-label dosing [spinal component]): </b> 1.75 to 2.5 mg combined with fentanyl 15 mcg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12540646','lexi-content-ref-24398818','lexi-content-ref-17697771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12540646','lexi-content-ref-24398818','lexi-content-ref-17697771'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Combined spinal-epidural (CSE) technique for anesthesia for Cesarean delivery (off-label dosing [spinal component]): </b> 8 to 12 mg combined with fentanyl 15 mcg; in addition to fentanyl, may also include a longer-acting opioid (ie, morphine 100 to 150 <b>mcg</b>) for postoperative analgesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15108985','lexi-content-ref-Santos.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15108985','lexi-content-ref-Santos.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Subacromial injection (Posimir): Infiltration:</b> Arthroscopic subacromial decompression surgery: 660 mg (5 mL) as a single dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991285"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Implant: There are no specific dosage adjustments provided in the manufacturer's labeling. Risk of adverse reactions may be increased in patients with renal impairment, particularly in patients with severe kidney disease. Consider increased monitoring for toxicities.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: There are no specific dosage adjustments provided in the manufacturer's labeling. Risk of adverse reactions may be increased in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Subacromial injection (Posimir): There are no specific dosage adjustments provided in the manufacturer's labeling. Risk of adverse reactions may be increased in patients with renal impairment, particularly in patients with severe kidney disease. Consider increased monitoring for toxicities.</p></div>
<div class="block doha drugH1Div" id="F50988600"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Implant: There are no specific dosage adjustments provided in the manufacturer's labeling. Risk of toxicity may be increased in patients with severe impairment; consider more frequent monitoring for toxicities in patients with moderate or severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: There are no specific dosage adjustments provided in the manufacturer's labeling. Risk of toxicity may be increased in patients with severe impairment; consider a reduced dose and more frequent monitoring for toxicities in patients with moderate or severe impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Subacromial injection (Posimir): There are no specific dosage adjustments provided in the manufacturer's labeling. Risk of toxicity may be increased in patients with severe impairment; consider a reduced dose and more frequent monitoring for toxicities in patients with moderate or severe impairment.</p></div>
<div class="block doe drugH1Div" id="F142928"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F142943"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13100" href="/d/html/13100.html" rel="external">see "Bupivacaine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose varies with procedure, depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient. Preservative-free formulations are recommended for administration into the CNS space (eg, epidural, caudal, spinal). Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20216035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20216035'])">Ref</a></span>). Should only be administered under the supervision of a qualified physician experienced in the use of anesthetics. In obese pediatric patients, the preferred weight used for dose calculation is undefined and specific pediatric data are sparse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29697466','lexi-content-ref-29200076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29697466','lexi-content-ref-29200076'])">Ref</a></span>); some have suggested the use of lean body mass/weight not ideal body weight (IBW) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937c3958-803e-4782-929b-d6857e35ccc3">Central nerve block/anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Central nerve block/anesthesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Caudal block:</i> Reported dosing variable based on procedure; dependent on necessary dermatome level and corresponding volume of space:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Limited data available: Usual concentration ≤0.25% solution with or without epinephrine: Usual reported dose range: 0.5 to 1.3 mL/kg (maximal volume of drug: 20 mL); dose should not exceed 2 <b>mg/kg</b> plain solution, or 3 <b>mg/kg</b> with epinephrine. In infants, routine use of concentrations ≤0.25% have been suggested to reduce risk of bupivacaine cardiotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2','lexi-content-ref-17263741','lexi-content-ref-9813532','lexi-content-ref-3605712','lexi-content-ref-24832387','lexi-content-ref-Miller.2015','lexi-content-ref-8437068','lexi-content-ref-12791113','lexi-content-ref-21199124']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2','lexi-content-ref-17263741','lexi-content-ref-9813532','lexi-content-ref-3605712','lexi-content-ref-24832387','lexi-content-ref-Miller.2015','lexi-content-ref-8437068','lexi-content-ref-12791113','lexi-content-ref-21199124'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Usual concentration 0.25% to 0.5% solution with or without epinephrine: 15 to 30 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Epidural block</i>: Reported dosing variable; among other factors, dose dependent on necessary dermatome level and corresponding volume of epidural space (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: Limited data available: Usual concentration ≤0.25% with or without epinephrine: 0.7 to 0.75 mL/kg; maximum dose: 2.5 <b>mg/kg</b>; <b>Note: </b>For infants (particularly young infants), if repeat injections necessary, a decreased dose may be necessary to prevent drug accumulation. Some experts suggest if at least 45 minutes since initial dose, reduce dose to <sup>1</sup>/<sub>3</sub> of the initial or if at least 90 minutes since initial dose, then reduce dose to half of the initial. If additional doses are necessary, doses should be reduced to half of the previous dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10349927','lexi-content-ref-Miller.2015','lexi-content-ref-17578955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10349927','lexi-content-ref-Miller.2015','lexi-content-ref-17578955'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children: Limited data available: Usual concentration 0.25% solution: Initial: 0.3 to 0.6 mL/kg (maximal volume of drug: 20 mL); maximum dose: 2.5 <b>mg/kg</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17986035','lexi-content-ref-17263741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17986035','lexi-content-ref-17263741'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: 0.25% or 0.5% solution: 10 to 20 mL administered in 3 to 5 mL increments; if high degree of muscle relaxation and prolonged effects needed, may consider 0.75% solution: 10 to 20 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Epidural, continuous infusion: </i>Limited data available in infants and children &lt;12 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1632529','lexi-content-ref-Cote.2','lexi-content-ref-Miller.2015','lexi-content-ref-22128779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1632529','lexi-content-ref-Cote.2','lexi-content-ref-Miller.2015','lexi-content-ref-22128779'])">Ref</a></span>): <b>Note:</b> Use has generally been replaced by other agents (eg, ropivacaine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Miller.2015','lexi-content-ref-22128779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Miller.2015','lexi-content-ref-22128779'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: Usual concentration: 0.25% solution: 2 to 2.5 <b>mg/kg.</b></p>
<p style="text-indent:-2em;margin-left:6em;">Infusion:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants &lt;6 months: 0.2 <b>mg</b>/kg/<b>hour</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months: 0.25 <b>mg</b>/kg/<b>hour</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents: 0.3 <b>mg</b>/kg/<b>hour</b>; range: 0.2 to 0.4 <b>mg</b>/kg/<b>hour</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="806550a8-bbde-4773-bac6-49d476407ccf">Local anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Local anesthesia</b>: Infants, Children, and Adolescents: Limited data in infants and children: Usual concentration 0.25% solution: Infiltrate local area; maximum dose in infants and children: 2.5 <b>mg/kg</b> or 150 mg, whichever is less; maximum dose in adolescents: 175 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f02645aa-c077-48bc-9473-f2947b0646de">Peripheral nerve block</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripheral nerve block: </b>Limited data available in infants and children: <b>Note:</b> Dose varies with location of block (ie, procedure), depth of anesthesia, vascularity of tissues, duration of anesthesia, and condition of patient.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and Children: Usual concentration 0.125% or 0.25% solution with or without epinephrine: The volume of dose (mL/kg) and concentration of solution are site specific based upon anatomy and variable among patients and procedure; see below ranges. For infants &lt;6 months, maximum doses should be reduced by 30% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2','lexi-content-ref-Miller.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2','lexi-content-ref-Miller.2015'])">Ref</a></span>). Maximum dose plain solution: 2 <b>mg/kg</b> or 150 mg, whichever is less, or maximum dose with epinephrine: 3 <b>mg/kg</b> or 200 mg of bupivacaine, whichever is less.</p>
<p style="text-indent:-2em;margin-left:6em;">Commonly suggested doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Head and neck:</i> 0.05 mL/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Upper extremity</i>:</p>
<p style="text-indent:-2em;margin-left:10em;">Brachial plexus: 0.2 to 0.3 mL/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Digital nerve: 0.05 mL/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Truncal blocks:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Transversus abdominis plane: 0.2 to 0.5 mL/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25693139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25693139'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Rectus sheath: 0.1 mL/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Ilioinguinal: 0.075 mL/kg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Lower extremity blocks</i>:</p>
<p style="text-indent:-2em;margin-left:10em;">Femoral nerve: 0.2 to 0.3 mL/kg.</p>
<p style="text-indent:-2em;margin-left:10em;">Sciatic nerve: 0.2 to 0.3 mL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: 0.25% or 0.5% solution with or without epinephrine: 5 mL; maximum daily dose: 400 <b>mg/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51084033"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51084034"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block adr drugH1Div" id="F142898"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Implant:</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%: Local: Edema at insertion site (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Dysgeusia (8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Scrotal edema (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Headache (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Tremor (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Blurred vision (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (2%), seroma (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined: Infection: Wound infection</p>
<p style="text-indent:-2em;margin-left:2em;">Injection:</p>
<p style="text-indent:-2em;margin-left:4em;">Reactions listed are based on reports for bupivacaine, bupivacaine/epinephrine, and/or other local anesthetics.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Pruritus (3% to 19%; including eye pruritus and anorectal pruritus)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Constipation (7% to 42%), dysgeusia (15% to 18%), nausea (39% to 60%, including post-procedural nausea), vomiting (10% to 29%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Dizziness (21% to 40%), drowsiness (32% to 41%), headache (6% to 32%), paresthesia (4% to 18%)</p>
<p style="text-indent:-2em;margin-left:6em;">Otic: Tinnitus (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Angina pectoris (&lt;2%), flattened T wave on ECG (&lt;2%), hypertension (4%), inversion T wave on ECG (4%), peripheral edema (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Injection site pruritus (3%), skin rash (4%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Upper abdominal pain (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Dysmenorrhea (3%), urinary retention (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Bruise (3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Fatigue (&lt;2%), hypoesthesia (≤17%), insomnia (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Limb pain (3%), muscle twitching (4%), musculoskeletal pain (5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Blepharospasm (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Cough (2%), dyspnea (4%), exacerbation of pulmonary arterial hypertension (&lt;2%), nasal congestion (3%), oropharyngeal pain (1%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (6% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Bradycardia, cardiac insufficiency, circulatory shock, heart block, hypotension, low cardiac output, ventricular arrhythmia</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Fecal incontinence, loss of anal sphincter control</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Prolonged labor, sexual disorder (loss of function), urinary incontinence</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic &amp; oncologic: Methemoglobinemia</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:6em;">Infection: Septic meningitis</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Anxiety, arachnoiditis, central nervous system depression, central nervous system stimulation, chills, coma, confusion, cranial nerve palsy, localized numbness (perineal), loss of consciousness, meningism, paralysis, paraplegia, persistent anesthesia, restlessness, seizure, shivering</p>
<p style="text-indent:-2em;margin-left:6em;">Neuromuscular &amp; skeletal: Asthenia, back pain, lower extremity weakness, tremor</p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic: Blurred vision, miosis</p>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Apnea, hypoventilation, respiratory depression, respiratory paralysis</p></div>
<div class="block coi drugH1Div" id="F142911"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to bupivacaine hydrochloride, amide-type local anesthetics, or any component of the formulation; obstetrical paracervical block anesthesia; IV regional anesthesia (Bier block) (injection only).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe shock and in heart block where there is inflammation and/or sepsis near the proposed injection site (Marcaine only).</p></div>
<div class="block war drugH1Div" id="F142895"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: Bupivacaine-containing products have been associated with rare occurrences of arrhythmias, cardiac arrest, and death.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is <b>not</b> an approved use; chondrolysis (primarily shoulder joint) has occurred following infusion, with some patients requiring arthroplasty or shoulder replacement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, light-headedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest, especially when administered near the head or neck.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection or administration near the head or neck.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease including patients with hypotension or heart block.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution in acutely ill patients; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; dose reduction may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP 1997; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Interchangeability: Subacromial injection is not interchangeable with other bupivacaine formulations; bioequivalence is not the same even when milligram dosage is the same.</p>
<p style="text-indent:-2em;margin-left:4em;">• Obstetrical anesthesia: The bupivacaine 0.75% concentration is not recommended for obstetrical anesthesia. There have been reports of cardiac arrest with difficult resuscitation or death during use of bupivacaine for epidural anesthesia in obstetrical patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Preservative-containing solutions: <b>Do not use solutions containing preservatives for caudal or epidural block.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium metabisulfite: May contain sodium metabisulfite; use caution in patients with asthma or a sulfite allergy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration:</p>
<p style="text-indent:-2em;margin-left:6em;">- Injection: Use the lowest effective dose and fractional (incremental) doses when possible; repeat administration may result in accumulation of bupivacaine and metabolites. Intravascular and intrathecal injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular or intrathecal injection has been avoided. IV regional anesthesia (Bier block) is contraindicated; cardiac arrest and death have occurred with this method of administration.</p>
<p style="text-indent:-2em;margin-left:6em;">- Subacromial injection: For infiltration into the subacromial space only; not for epidural, intra-articular, intrathecal, intravascular, or regional nerve block administration. Avoid inadvertent intravascular administration; cardiac arrest and seizures have occurred. May be used with implantable materials (eg, polypropylene, polyester) and gut, nylon, polydioxanone, polypropylene, polyglycolic acid, and silk sutures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Test dose: A test dose is recommended prior to epidural administration (prior to initial dose) and all reinforcing doses with continuous catheter technique.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878356"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Infants may be at greater risk for bupivacaine toxicity because α<sub>1</sub>-acid-glycoprotein concentration, the major serum protein to which bupivacaine is bound, is lower in neonates and infants compared with older children leading to an increase of free fraction of local anesthetic; use epidural infusions with caution in neonates and infants and monitor closely. Fat emulsion has been used to manage local anesthetic toxicity (refer to Lipid Emulsion (Plant Based) monograph for additional information) (McCloskey 1992).</p></div>
<div class="block foc drugH1Div" id="F142906"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Implant, Implant: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xaracoll: 300 mg (3 x 100 mg) (3 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">P-Care M: 0.5% [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Posimir: 660 mg/5 mL (5 mL) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine: 0.25% (50 mL); 0.5% (50 mL) [contains methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sensorcaine: 0.25% (50 mL); 0.5% (50 mL) [contains methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25% (50 mL); 0.5% (30 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">BUPivacaine Fisiopharma: 2.5 mg/mL (5 mL, 10 mL); 5 mg/mL (5 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine: 0.75% (10 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine Preservative Free: 0.25% (10 mL, 30 mL); 0.5% (10 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sensorcaine-MPF: 0.25% (10 mL, 30 mL); 0.5% (10 mL, 30 mL); 0.75% (10 mL, 30 mL) [methylparaben free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25% (10 mL, 30 mL); 0.5% (10 mL, 30 mL); 0.75% (10 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intrathecal, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.75% [7.5 mg/mL] (2 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intrathecal, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">BUPivacaine Spinal: 0.75% [7.5 mg/mL] (2 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine Spinal: 0.75% [7.5 mg/mL] (2 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.75% [7.5 mg/mL] (2 mL)</p></div>
<div class="block geq drugH1Div" id="F142891"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323027"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (Xaracoll Implant)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 x 100 mg (per each): $99.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (BUPivacaine HCl (PF) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $0.07 - $0.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.09 - $0.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75% (per mL): $0.29 - $0.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (BUPivacaine HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $0.09 - $0.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.07 - $0.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (BUPivacaine in Dextrose Intrathecal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75-8.25% (per mL): $3.12</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Marcaine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $0.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75% (per mL): $0.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Marcaine Preservative Free Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $0.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Marcaine Spinal Intrathecal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75-8.25% (per mL): $0.87</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Posimir Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">660 mg/5 mL (per mL): $76.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sensorcaine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $0.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.31</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sensorcaine-MPF Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $0.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.75% (per mL): $0.30</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866128"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine: 0.75% (20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.75% (10 mL, 20 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine: 0.25% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine: 0.25% ([DSC]) [contains methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine: 0.5% ([DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine: 0.5% (50 mL) [contains methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sensorcaine: 0.25% (10 mL, 20 mL); 0.5% (10 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25% (10 mL, 20 mL); 0.5% (10 mL, 20 mL); 0.75% (10 mL, 20 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intrathecal, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Marcaine Spinal: 0.75% [7.5 mg/mL] (2 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.75% [7.5 mg/mL] (2 mL)</p></div>
<div class="block adm drugH1Div" id="F142908"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Implant:</b> Each single-dose pouch is supplied as a sterile product that should be handled using aseptic technique. Oxygen and resuscitative medications, staff, and equipment should be immediately available. Implant is a ready-to-use product and only requires cutting the individual implants as needed to accommodate the surgical space. Aseptically peel outer pouch, remove and peel open inner blister pack; do not use scissors or scalpel to open the blister packaging. Inspect each implant prior to use; do not use if packaging has been compromised, or if implant appears discolored, contains foreign particles, or is collapsed, compressed, or misshapen; avoid excessive handling and compression. Aseptically cut each implant in half prior to placement into the surgical site; place 3 halves below the site of mesh placement and 3 halves just below the skin closure. Place dry implant into surgical site; when a topical antiseptic (eg, povidone iodine) is applied, allow surgical site to dry before implantation. Avoid contact with liquids prior to placement; pre-moistening may result in premature release of bupivacaine. Avoid additional local anesthetic administration within 96 hours of inserting implant; toxic effects of local anesthetics are additive. If additional local anesthetic administration cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity. Depending on clinical situation, consider surgical removal of implant if systemic toxicity occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection:</b> Solutions containing preservatives should not be used for epidural or caudal blocks. Addition of sodium bicarbonate to increase speed of onset may cause precipitation as pH approaches physiologic range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2562097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2562097'])">Ref</a></span>). The On-Q infusion pump is used to slowly administer local anesthetics (eg, bupivacaine, lidocaine, ropivacaine) to or around surgical wound sites and/or in close proximity to peripheral nerves for postoperative analgesia. When infused directly into the shoulder, destruction of articular cartilage (chondrolysis) has occurred. On-Q pumps should never be placed directly into any joint (see https://www.ismp.org/Newsletters/acutecare/archives/May09.asp).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Subacromial injection (Posimir</b>
<b>):</b> For infiltration into the subacromial space only following arthroscopic subacromial decompression surgery; not for epidural, intra-articular, intrathecal, intravascular, or regional nerve block administration. Do not use for pre-incisional or pre-procedural locoregional anesthetic techniques that require deep or complete sensory block. Do not dilute or mix with other drugs, diluents, or local anesthetics. Do not interchange with other bupivacaine formulations. Avoid use with other local anesthetics within 168 hours following administration. Draw up 5 mL into a syringe containing a large bore needle (≥16 gauge); discard needle. At the close of arthroscopic subacromial decompression surgery, administer entire dose into the subacromial space using an ≥18-gauge needle. Insert needle through an existing arthroscopic port or intact skin to reach the subacromial space; confirm placement with direct arthroscopic visualization; avoid administering into the glenohumeral intra-articular space.</p></div>
<div class="block admp drugH1Div" id="F52612328"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Solutions containing preservatives should not be used for epidural or caudal blocks; for epidural infusion, may use undiluted or diluted with preservative-free NS. Consider incremental administration with negative aspiration prior to each injection; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20216035']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20216035'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F142907"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">Implant (Xaracoll): Placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Local or regional anesthesia; spinal anesthesia (0.75% in dextrose 8.25% injection); diagnostic and therapeutic procedures; obstetrical procedures (only 0.25% and 0.5% concentrations).</p>
<p style="text-indent:-2em;margin-left:4em;">0.25%: Local infiltration, peripheral nerve block, sympathetic block, caudal or epidural block.</p>
<p style="text-indent:-2em;margin-left:4em;">0.5%: Peripheral nerve block, caudal and epidural block.</p>
<p style="text-indent:-2em;margin-left:4em;">0.75% <b>(not for obstetrical anesthesia)</b>: Retrobulbar block, epidural block. <b>Note:</b> Reserve for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Subacromial injection (Posimir): Infiltration administration in adults into the subacromial space under direct arthroscopic visualization to produce post-surgical analgesia for up to 72 hours following arthroscopic subacromial decompression.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Limitations of use:</i> Safety and efficacy have not been established in other surgical procedures, including soft tissue surgical procedures, other orthopedic procedures, including for intra-articular administration, and boney procedures, or when used for neuraxial or peripheral nerve blockade.</p></div>
<div class="block mst drugH1Div" id="F142970"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">BUPivacaine may be confused with mepivacaine, ROPivacaine</p>
<p style="text-indent:-2em;margin-left:4em;">Marcaine may be confused with Narcan</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F142957"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F142900"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): BUPivacaine may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Bupivacaine may be administered immediately before, or administered in the same admixture syringe as liposomal bupivacaine as long as the ratio of the milligram dose of bupivacaine to liposomal bupivacaine does not exceed 1:2.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: May enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxyurea: May enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: May enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: May enhance the adverse/toxic effect of BUPivacaine. Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrous Oxide: May enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: May increase the serum concentration of BUPivacaine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F2233562"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Bupivacaine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Small amounts of bupivacaine can be found in maternal plasma following epidural, caudal, or pudendal nerve block anesthesia, and potentially causing varying degrees of maternal, fetal, and neonatal toxicity involving the CNS, peripheral vascular tone, and cardiac function.</p>
<p style="text-indent:0em;margin-top:2em;">Bupivacaine is approved for use at term in obstetrical anesthesia or analgesia. It is used as a component of regional anesthesia for labor analgesia and operative anesthesia, for intra-incisional analgesia at the end of a cesarean section, and for pudendal nerve blocks used in the second stage of labor or for repairing perineal lacerations (ACOG 2019). Use in obstetrical paracervical block anesthesia is contraindicated (may cause fetal bradycardia and death).</p>
<p style="text-indent:0em;margin-top:2em;">The bupivacaine 0.75% concentration is not recommended for obstetrical anesthesia. <b>There have been reports of cardiac arrest with difficult resuscitation or death during use of bupivacaine for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% concentration should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</b></p></div>
<div class="block brc drugH1Div" id="F20688278"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Bupivacaine and its active metabolite are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Breast milk concentrations of bupivacaine were evaluated in a study of 27 women (~38 weeks gestation) administered bupivacaine 0.5% combined with lidocaine 2% for local anesthesia prior to cesarean delivery. Maternal serum and breast milk were sampled prior to, then at 2, 6, and 12 hours after the epidural infusion. Peak breast milk concentrations occurred 2 hours after the maternal dose for bupivacaine and 12 hours after the dose for the active metabolite. Adverse events were not observed in the breastfed infants (Ortega 1999). In a second study, bupivacaine was not detected in the serum of a breastfed 10-month old infant, feeding 4 times daily following maternal use of a continuous intrapleural bupivacaine 0.25% infusion (10 mL/hour) after a cholecystectomy. Breastfeeding resumed ~22 hours after the maternal infusion began; infant blood was sampled ~5 hours after a morning feed and ~52 hours after a maternal bolus dose (Baker 1989).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. However, the Academy of Breast Feeding Medicine considers local anesthetics such as bupivacaine compatible with breastfeeding. Elective surgery should be postponed until milk supply and breastfeeding are established. Milk should be expressed ahead of surgery when possible. In general, when the child is healthy and full term, breastfeeding may resume, or milk may be expressed once the mother is awake and in recovery. For children who are at risk for apnea, hypotension, or hypotonia, milk may be saved for later use when the child is at lower risk (ABM [Reece-Stremtan 2017]).</p></div>
<div class="block mop drugH1Div" id="F142904"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs, state of consciousness; signs of CNS toxicity</p></div>
<div class="block pha drugH1Div" id="F142894"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction</p></div>
<div class="block phk drugH1Div" id="F142910"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Anesthesia (route and dose dependent):</p>
<p style="text-indent:-2em;margin-left:4em;">Epidural: Up to 17 minutes to spread to T6 dermatome (Scott 1980).</p>
<p style="text-indent:-2em;margin-left:4em;">Infiltration: Fast (Barash 2009); Dental injection: 2 to 10 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Spinal: Within 1 minute; maximum dermatome level achieved within 15 minutes in most cases.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration (route and dose dependent):</p>
<p style="text-indent:-2em;margin-left:4em;">Epidural: 2 to 7.7 hours (Barash 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">Implant: Variable: Up to ~72 hours (Velanovich 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Infiltration: 2 to 8 hours (Barash 2009); Dental injection: Up to 7 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Spinal: 1.5 to 2.5 hours (Tsai 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Subacromial injection: ~72 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Infants: 3.9 ± 2 L/kg; Children: 2.7 ± 0.2 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 84% to 95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; forms metabolite (pipecoloxylidine [PPX]).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination (age dependent): Implant: 19 hours; Injection: Neonates: 8.1 hours; Adults: 2.7 hours; Subacromial injection: 16.4 to 26.1 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Caudal, epidural, or peripheral nerve block: 30 to 45 minutes; Implant: Median: 3 hours (range: 1.5 to 24 hours); Subacromial injection: Median: ~6 to 8 hours (range: 1 to ~27 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~6% unchanged).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Infants: 7.1 ± 3.2 mL/kg/minute; Children: 10 ± 0.7 mL/kg/minute.</p></div>
<div class="block phksp drugH1Div" id="F51154131"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Elderly patients reached the maximal spread of analgesia and maximal motor blockade more rapidly than younger patients. Elderly patients also exhibited higher peak plasma concentrations following administration of this product. The total plasma clearance was decreased in these patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038543"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bupigobbi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bupivacain Sintetica</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Kolac</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Marcaine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Marcain</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Exparel liposomal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Buvanest</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bupitroy</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Bucaine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Betolina</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bucain Hyperbar</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bupivacain hcl | Bupivacain hcl pch | Bupivacaine Accord | Bupivacaine hcl grindeks | Bupivacaine hcl svizera</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Marcain | Marcaine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Marcain</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Marcaine | Sensorcaine</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Bupivacaine HCL | Sensorcaine | Sensorcaine mpf | Xaracoll</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Betolina | Bucaine | Bucaine PF | Bupicaine Rachianestesia | Bupican | Bupican Heavy | Buvasin Heavy | Marcain | Marcain Heavy | Marcaine PF</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Marcaine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Novostezin Spinal Heavy</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Anawin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin no. 209: Obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2019;133(3):e208-e225. doi: 10.1097/AOG.0000000000003132</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2774239">
<a name="2774239"></a>Baker PA, Schroeder D. Interpleural bupivacaine for postoperative pain during lactation. <i>Anesth Analg</i>. 1989;69(3):400-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/2774239/pubmed" id="2774239" target="_blank">2774239</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Barash PG, Cullen BF, Stoelting RK, et al, eds. <i>Clinical Anesthesia</i>. 6th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1632529">
<a name="1632529"></a>Berde CB, “Convulsions Associated With Pediatric Regional Anesthesia,” <i>Anesth Analg</i>, 1992, 75(2):164-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/1632529/pubmed" id="1632529" target="_blank">1632529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15105200">
<a name="15105200"></a>Bonnet MP, Larousse E, Asehnoune K, Benhamou D. Spinal anesthesia with bupivacaine decreases cerebral blood flow in former preterm infants. <i>Anesth Analg</i>. 2004;98(5):1280-1283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/15105200/pubmed" id="15105200" target="_blank">15105200</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Bupivacaine injection, solution [prescribing information]. Lake Forest, IL: Hospira, Inc.; October 2016.</div>
</li>
<li>
<div class="reference">
                  Bupivacaine Spinal injection, solution [prescribing information]. Lake Forest, IL: Hospira, Inc.; January 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.1">
<a name="Cote.1"></a>Coté CJ, ed. <i>A Practice of Anesthesia for Infants and Children</i>. 5th ed. Philadelphia, PA: Elsevier Inc; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.2">
<a name="Cote.2"></a>Coté CJ, ed. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier Inc; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18950332">
<a name="18950332"></a>Deng M, Wang X, Wang L, Zheng S. The hemodynamic effects of newborn caudal anesthesia assessed by transthoracic echocardiography: a randomized, double-blind, controlled study. <i>Paediatr Anaesth</i>. 2008;18(11):1075-1081.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/18950332/pubmed" id="18950332" target="_blank">18950332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21263316">
<a name="21263316"></a>Dix SK, Rosner GF, Nayar M, et al, “Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,” <i>Crit Care Med</i>, 2011, 39(4):872-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/21263316/pubmed" id="21263316" target="_blank">21263316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12540646">
<a name="12540646"></a>Eltzschig HK, Lieberman ES, Camann WR. Regional anesthesia and analgesia for labor and delivery. <i>N Engl J Med</i>. 2003;348(4):319-332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/12540646/pubmed" id="12540646" target="_blank">12540646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17448066">
<a name="17448066"></a>Foxall G, McCahon R, Lamb J, et al, “Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,” <i>Anaesthesia</i>, 2007, 62(5):516-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/17448066/pubmed" id="17448066" target="_blank">17448066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19767606">
<a name="19767606"></a>Frawley G, Smith KR, Ingelmo P. Relative potencies of bupivacaine, levobupivacaine, and ropivacaine for neonatal spinal anaesthesia. <i>Br J Anaesth</i>. 2009;103(5):731-738.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/19767606/pubmed" id="19767606" target="_blank">19767606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15108985">
<a name="15108985"></a>Ginosar Y, Mirikatani E, Drover DR, Cohen SE, Riley ET. ED50 and ED95 of intrathecal hyperbaric bupivacaine coadministered with opioids for cesarean delivery. <i>Anesthesiology</i>. 2004;100(3):676-682. doi:10.1097/00000542-200403000-00031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/15108985/pubmed" id="15108985" target="_blank">15108985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17986035">
<a name="17986035"></a>Ingelmo P, Locatelli BG, Frawley G, et al. The optimum initial pediatric epidural bolus: a comparison of four local anesthetic solutions. <i>Paediatr Anaesth</i>. 2007a;17(12):1166-1175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/17986035/pubmed" id="17986035" target="_blank">17986035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17263741">
<a name="17263741"></a>Ingelmo PM, Bendall EJ, Frawley G, et al. Bupivacaine caudal epidural anesthesia: assessing the effect of general anesthetic technique on block onset. <i>Paediatr Anaesth</i>. 2007b;17(3):255-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/17263741/pubmed" id="17263741" target="_blank">17263741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3605712">
<a name="3605712"></a>Ivani G, DeNegri P, Conio A, et al. Comparison of racemic bupivacaine, ropivacaine, and levo-bupivacaine for pediatric caudal anesthesia: effects on postoperative analgesia and motor block. <i>Reg Anesth Pain Med</i>. 2002;27(2):157-161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/ 3605712 /pubmed" id=" 3605712 " target="_blank"> 3605712 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10349927">
<a name="10349927"></a>Ivani G, Lampugnani E, De Negri P, Lonnqvist PA, Broadman L. Ropivacaine vs bupivacaine in major surgery in infants. <i>Can J Anaesth</i>. 1999;46(5 Pt 1):467-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/10349927/pubmed" id="10349927" target="_blank">10349927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9813532">
<a name="9813532"></a>Ivani G, Lampugnani E, Torre M, et al. Comparison of ropivacaine with bupivacaine for paediatric caudal block. <i>Br J Anaesth</i>. 1998;81(2):247-248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/9813532/pubmed" id="9813532" target="_blank">9813532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25693139">
<a name="25693139"></a>Jöhr M. Regional anaesthesia in neonates, infants and children: an educational review. <i>Eur J Anaesthesiol</i>. 2015;32(5):289-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/25693139/pubmed" id="25693139" target="_blank">25693139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24832387">
<a name="24832387"></a>Karkera MM, Harrison DR, Aunspaugh JP, Martin TW. Assessing caudal block concentrations of bupivacaine with and without the addition of intravenous fentanyl on postoperative outcomes in pediatric patients: a retrospective review. <i>Am J Ther</i>. 2016;23(3):e792-e798.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/24832387/pubmed" id="24832387" target="_blank">24832387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18644530">
<a name="18644530"></a>Kost-Byerly S, Jackson EV, Yaster M, Kozlowski LJ, Mathews RI, Gearhart JP. Perioperative anesthetic and analgesic management of newborn bladder exstrophy repair. <i>J Pediatr Urol</i>. 2008;4(4):280-285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/18644530/pubmed" id="18644530" target="_blank">18644530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7716603">
<a name="7716603"></a>Lehmann LJ and Pallares VS, “Subdural Injection of a Local Anesthetic With Steroids: Complication of Epidural Anesthesia,” <i>South Med J</i>, 1995, 88(4):467-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/7716603/pubmed" id="7716603" target="_blank">7716603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29697466">
<a name="29697466"></a>Lerman J, Becke K. Perioperative considerations for airway management and drug dosing in obese children. <i>Curr Opin Anaesthesiol</i>. 2018;31(3):320-326.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/29697466/pubmed" id="29697466" target="_blank">29697466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20849501">
<a name="20849501"></a>Lin EP, Aronson LA. Successful resuscitation of bupivacaine-induced cardiotoxicity in a neonate. <i>Paediatr Anaesth</i>. 2010;20(10):955-957.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/20849501/pubmed" id="20849501" target="_blank">20849501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16867094">
<a name="16867094"></a>Litz RJ, Popp M, Stehr SN, et al, “Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,” <i>Anaesthesia</i>, 2006, 61(8):800-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/16867094/pubmed" id="16867094" target="_blank">16867094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2774240">
<a name="2774240"></a>Long WB, Rosenblum S, and Grady IP, “Successful Resuscitation of Bupivacaine-Induced Cardiac Arrest Using Cardiopulmonary Bypass,” <i>Anesth Analg</i>, 1989, 69(3):403-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/2774240/pubmed" id="2774240" target="_blank">2774240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21033009">
<a name="21033009"></a>Lönnqvist PA. Regional anaesthesia and analgesia in the neonate. <i>Best Pract Res Clin Anaesthesiol</i>. 2010;24(3):309-321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/21033009/pubmed" id="21033009" target="_blank">21033009</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Marcaine (bupivacaine) [prescribing information]. Lake Forest, IL: Hospira Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Marcaine.2">
<a name="Marcaine.2"></a>Marcaine (bupivacaine) [product monograph]. Kirkland, Québec, Canada: Pfizer Canada ULC; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Marcaine.3">
<a name="Marcaine.3"></a>Marcaine Spinal (bupivacaine) [prescribing information]. Lake Forest, IL: Hospira Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1340763">
<a name="1340763"></a>McCloskey JJ, Haun SE, Deshpande JK. Bupivacaine toxicity secondary to continuous caudal epidural infusion in children. <i>Anesth Analg</i>. 1992;75(2):287-290. doi:10.1213/00000539-199208000-00024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/1340763/pubmed" id="1340763" target="_blank">1340763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.2015">
<a name="Miller.2015"></a>Miller RD, ed. <i>Miller's Anesthesia</i>. 8th ed. Philadelphia, PA: Elsevier, Inc; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20332339">
<a name="20332339"></a>Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, “State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,” <i>Ann Pharmacother</i>, 2010, 44(4):688-700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/20332339/pubmed" id="20332339" target="_blank">20332339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17578955">
<a name="17578955"></a>Monsel A, Salvat-Toussaint A, Durand P, et al. The transesophageal Doppler and hemodynamic effects of epidural anesthesia in infants anesthetized with sevoflurane and sufentanil.<i> Anesth Analg</i>. 2007;105(1):46-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/17578955/pubmed" id="17578955" target="_blank">17578955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20831923">
<a name="20831923"></a>Moore PA and Hersh EV, "Local Anesthetics: Pharmacology and Toxicity," <i>Dent Clin North Am</i>, 2010, 54(4):587-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/20831923/pubmed" id="20831923" target="_blank">20831923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22128779">
<a name="22128779"></a>Moriarty A. Pediatric epidural analgesia (PEA). <i>Paediatr Anaesth</i>. 2012;22(1):51-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/22128779/pubmed" id="22128779" target="_blank">22128779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20216035">
<a name="20216035"></a>Mulroy MF, Hejtmanek MR. Prevention of local anesthetic systemic toxicity. <i>Reg Anesth Pain Med</i>. 2010;35(2):177-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/20216035/pubmed" id="20216035" target="_blank">20216035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29200076">
<a name="29200076"></a>Nafiu OO, Mills K, Tremper KK. Some cautionary tales about ideal body weight dosing of anesthetic medications: it is not all that ideal!. <i>Anesth Analg</i>. 2018;127(2):586-588.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/29200076/pubmed" id="29200076" target="_blank">29200076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22189574">
<a name="22189574"></a>Neal JM, Mulroy MF, and Weinberg GL, “American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,” <i>Reg Anesth Pain Med</i>, 2012, 37(1):16-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/22189574/pubmed" id="22189574" target="_blank">22189574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24398818">
<a name="24398818"></a>Ngan Kee WD, Khaw KS, Ng FF, Ng KK, So R, Lee A. Synergistic interaction between fentanyl and bupivacaine given intrathecally for labor analgesia. <i>Anesthesiology</i>. 2014;120(5):1126-1136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/24398818/pubmed" id="24398818" target="_blank">24398818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10225071">
<a name="10225071"></a>Ortega D, Viviand X, Lorec AM, Gamerre M, Martin C, Bruguerolle B. Excretion of lidocaine and bupivacaine in breast milk following epidural anesthesia for cesarean delivery. <i>Acta Anaesthesiol Scand</i>. 1999;43(4):394-397. doi: 10.1034/j.1399-6576.1999.430405.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/10225071/pubmed" id="10225071" target="_blank">10225071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8437068">
<a name="8437068"></a>Payne KA, Hendrix MR, Wade WJ. Caudal bupivacaine for postoperative analgesia in pediatric lower limb surgery. <i>J Pediatr Surg</i>. 1993;28(2):155-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/8437068/pubmed" id="8437068" target="_blank">8437068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2562097">
<a name="2562097"></a>Peterfreund RA, Datta S, Ostheimer GW. pH adjustment of local anesthetic solutions with sodium bicarbonate: laboratory evaluation of alkalinization and precipitation. <i>Reg Anesth</i>. 1989;14(6):265-270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/2562097/pubmed" id="2562097" target="_blank">2562097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Posimir.1">
<a name="Posimir.1"></a>Posimir (bupivacaine) [prescribing information]. Cupertino, CA: Durect Corporation; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506. doi: 10.1089/bfm.2017.29054.srt<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16324026">
<a name="16324026"></a>Rochette A, Troncin R, Raux O, et al. Clonidine added to bupivacaine in neonatal spinal anesthesia: a prospective comparison in 124 preterm and term infants. <i>Paediatr Anaesth</i>. 2005;15(12):1072-1077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/16324026/pubmed" id="16324026" target="_blank">16324026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16810015">
<a name="16810015"></a>Rosenblatt MA, Abel M, Fischer GW, et al, “Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,” <i>Anesthesiology</i>, 2006, 105(1):217-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/16810015/pubmed" id="16810015" target="_blank">16810015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Santos.1">
<a name="Santos.1"></a>Santos AC, Epstein J, Chaudhuri K, eds. <i>Obstetric Anesthesia</i>. New York, NY: McGraw-Hill Education, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1148109">
<a name="1148109"></a>Scott DB, “Evaluation of Clinical Tolerance of Local Anaesthetic Agents,” <i>Br J Anaesth</i>, 1975, 47:328-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/1148109/pubmed" id="1148109" target="_blank">1148109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12791113">
<a name="12791113"></a>Schrock CR, Jones MB. The dose of caudal epidural analgesia and duration of postoperative analgesia. <i>Paediatr Anaesth</i>. 2003;13(5):403-408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/12791113/pubmed" id="12791113" target="_blank">12791113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21199124">
<a name="21199124"></a>Schwartz DA, Raghunathan K, Connelly NR. Reply to 'Successful resuscitation of bupivacaine-induced cardiotoxicity in a neonate'. <i>Paediatr Anaesth</i>. 2010;20(12):1136-1137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/21199124/pubmed" id="21199124" target="_blank">21199124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2679230">
<a name="2679230"></a>Scott DB, Lee A, Fagan D, et al, “Acute Toxicity of Ropivacaine Compared With That of Bupivacaine,” <i>Anesth Analg</i>, 1989, 69(5):563-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/2679230/pubmed" id="2679230" target="_blank">2679230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sensorcaine.1">
<a name="Sensorcaine.1"></a>Sensorcaine and Sensorcaine-MPF (bupivacaine) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; November 2022.</div>
</li>
<li>
<div class="reference">
                  Sensorcaine (bupivacaine) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17897271">
<a name="17897271"></a>Somri M, Tome R, Yanovski B, et al. Combined spinal-epidural anesthesia in major abdominal surgery in high-risk neonates and infants. <i>Paediatr Anaesth</i>. 2007;17(11):1059-1065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/17897271/pubmed" id="17897271" target="_blank">17897271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7485961">
<a name="7485961"></a>Sun KO, “Convulsion Following Spinal Anaesthesia,” <i>Anaesth Intensive Care</i>, 1995, 23(4):520-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/7485961/pubmed" id="7485961" target="_blank">7485961</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tsai T, Greengrass R. Spinal Anesthesia. In: Hadzic A, ed. <i>Regional Anesthesia and Acute Pain Management</i>. McGraw-Hill Education, 2007. http://accessanesthesiology.mhmedical.com/content.aspx?bookid=413&amp;sectionid=39828160.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1859023">
<a name="1859023"></a>Tuominen MK, Pere P, and Rosenberg PH, “Unintentional Arterial Catheterization and Bupivacaine Toxicity Associated With Continuous Interscalene Brachial Plexus Block,” <i>Anesthesiology</i>, 1991, 75(2):356-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/1859023/pubmed" id="1859023" target="_blank">1859023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30467808">
<a name="30467808"></a>Velanovich V, Rider P, Deck K, et al. Safety and efficacy of bupivacaine HCl collagen-matrix implant (INL-001) in open inguinal hernia repair: results from two randomized controlled trials. <i>Adv Ther</i>. 2019;36(1):200-216. doi:10.1007/s12325-018-0836-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/30467808/pubmed" id="30467808" target="_blank">30467808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22798528">
<a name="22798528"></a>Walker SM, Yaksh TL. Neuraxial analgesia in neonates and infants: a review of clinical and preclinical strategies for the development of safety and efficacy data. <i>Anesth Analg</i>. 2012;115(3):638-662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/22798528/pubmed" id="22798528" target="_blank">22798528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17697771">
<a name="17697771"></a>Whitty R, Goldszmidt E, Parkes RK, Carvalho JC. Determination of the ED95 for intrathecal plain bupivacaine combined with fentanyl in active labor.<i> Int J Obstet Anesth</i>. 2007;16(4):341-345.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/17697771/pubmed" id="17697771" target="_blank">17697771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11573526">
<a name="11573526"></a>Williams JM, Stoddart PA, Williams SA, Wolf AR. Post-operative recovery after inguinal herniotomy in ex-premature infants: comparison between sevoflurane and spinal anaesthesia. <i>Br J Anaesth</i>. 2001;86(3):366-371.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bupivacaine-drug-information/abstract-text/11573526/pubmed" id="11573526" target="_blank">11573526</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Xaracoll (bupivacaine) implant [prescribing information]. Athlone, Ireland: Innocoll Pharmaceuticals Limited; September 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9169 Version 504.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
